Meriofert Set

Human Menopausal Gonadotropin (hMG), the active ingredient in Meriofert Set, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It stimulates ovarian follicular development to induce ovulation in women and supports spermatogenesis in men.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this injectable fertility agent. Customers benefit from consistent product availability and regulatory compliance across EU and global markets.

Meriofert Set, a gonadotropin used in reproductive medicine, is indicated for the following clinical situations:

Induction of ovulation in anovulatory women: promotes follicular growth and estrogen production to achieve a timed ovulatory response. Controlled ovarian stimulation for assisted reproductive technologies: enhances development of multiple follicles, increasing the number of oocytes retrieved for IVF or ICSI procedures. Stimulation of spermatogenesis in male hypogonadism: provides LH and FSH activity to stimulate Leydig and Sertoli cells, improving testosterone levels and sperm output.

Like other gonadotropin preparations, Meriofert Set may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain or bruising - Mild abdominal discomfort or bloating - Nausea or vomiting - Headache - Mild ovarian hyperstimulation (e.g., mild ovarian enlargement)

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe) - Multiple pregnancy - Severe allergic reaction (anaphylaxis) - Thromboembolic events - Ectopic pregnancy

Prior to initiating therapy with Meriofert Set, several precautionary measures should be observed. - Pregnancy testing: confirm non‑pregnant status before starting treatment. - Baseline ovarian assessment: perform ultrasound to evaluate follicle count and size. - Monitor estradiol levels: regular blood tests to detect excessive response. - Adjust dose in patients with ovarian cysts or polycystic ovary syndrome. - Caution in patients with thromboembolic risk: assess history before use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - GnRH agonists: may amplify ovarian response and increase risk of severe hyperstimulation. - Estrogen‑containing contraceptives: antagonize gonadotropin action, reducing effectiveness. - Anticoagulants: heightened risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: monitor blood glucose as hormonal changes can affect control. - Corticosteroids: may alter ovarian response, requiring dose adjustment. - Thyroid hormone therapy: assess thyroid function as gonadotropins can influence metabolism.